QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, A. N. Articles by Miners, J. O. Search for Related Content PubMed PubMed Citation Articles by Stone, A. N. Articles by Miners, J. O.

SHORT COMMUNICATION

ISOFORM SELECTIVITY AND KINETICS OF MORPHINE 3- AND 6-GLUCURONIDATION BY HUMAN UDP-GLUCURONOSYLTRANSFERASES: EVIDENCE FOR ATYPICAL GLUCURONIDATION KINETICS BY UGT2B7

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Morphine elimination involves UDP-glucuronosyltransferase (UGT) catalyzed conjugation with glucuronic acid to form morphine 3- and 6-glucuronides (M3G and M6G, respectively). It has been proposed that UGT2B7 is the major enzyme involved in these reactions, but there is evidence to suggest that other isoforms also catalyze morphine glucuronidation in man. Thus, we have characterized the selectivity and kinetics of M3G and M6G formation by recombinant human UGTs. UGT 1A1, 1A3, 1A6, 1A8, 1A9, 1A10, and 2B7 all catalyzed M3G formation, but only UGT2B7 formed M6G. The kinetics of M3G formation by the UGT1A family isoforms was consistent with a single enzyme Michaelis-Menten model, with apparent K_m values ranging from 2.6 to 37.4 mM. In contrast, M3G and M6G formation by UGT2B7 exhibited atypical kinetics. The atypical kinetics may be described by a model with high- and low-affinity K_m values (0.42 and 8.3 mM for M3G, and 0.97 and 7.4 mM for M6G) from fitting to a biphasic Michaelis-Menten model. However, a multisite model with an interaction between two identical binding sites in a negative cooperative manner provides a more realistic approach to modeling these data. According to this model, the respective binding affinities (K_s) for M3G and M6G were 1.76 and 1.41 mM, respectively. These data suggest that M6G formation may be used as a selective probe for UGT2B7 activity, and morphine glucuronidation by UGT2B7 appears to involve the simultaneous binding of two substrate molecules, highlighting the need for careful analysis of morphine glucuronidation kinetics in vitro.

Morphine is the preferred opioid for the relief of moderate to severe pain. Conversion to morphine 3- and 6-glucuronides (M3G and M6G, respectively) accounts for approximately two-thirds of the elimination of a parenteral dose of morphine in humans (Milne et al., 1996). Morphine 3-glucuronidation is the dominant pathway, and metabolic clearance to M3G is, on average, 5.4-fold higher than metabolic clearance to M6G. Although the liver appears to be the principal organ responsible for morphine glucuronidation in vivo, the gastrointestinal tract may contribute significantly to first-pass extraction after oral administration (Milne et al., 1996). Given the therapeutic importance of morphine and recognition that M6G also possesses analgesic activity, identification of the human UGT isoform(s) involved in the formation of the morphine glucuronides has attracted considerable interest. UGT2B7 has been shown to catalyze the conversion of morphine to both M3G and M6G and has been proposed as the major isoform involved in the glucuronidation of morphine in man (Coffman et al., 1997, 1998).

Although morphine is occasionally used as a substrate probe for UGT2B7, there have been no systematic studies of the UGT isoforms involved in morphine 3- and 6-glucuronidation. Indeed, there is evidence indicating that other isoforms have the capacity to glucuronidate morphine (Green et al., 1998; Cheng et al., 1999), and the apparent biphasic M3G formation kinetics in human liver microsomes (Miners et al., 1988) further suggests that multiple isoforms may catalyze the formation of this metabolite. We describe studies that aimed to characterize the selectivity and kinetics of M3G and M6G formation by recombinant human UGTs.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemicals. Morphine hemisulfate was a gift from Faulding Pharmaceuticals (Adelaide, Australia). M6G was purchased from Ultrafine Chemicals (Manchester, UK), and M3G, UDP-glucuronic acid (UDPGA), 4-methylumbelliferone (4MU), and 4MU-ß-D-glucuronide (4MUG) were purchased from Sigma-Aldrich (St. Louis, MO). Other chemicals and reagents were of analytical reagent grade.

Expression of UGTs. UGT 1A1, 1A3, 1A6, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, and 2B15 were stably expressed in HK293 cells. Cells were transfected with cDNAs cloned into the pEF-IRES-puro6 expression vector, and microsomes from cells expressing UGT1A family isoforms were prepared as described previously (Sorich et al., 2002). However, the microsome preparation procedure resulted in significant loss of activity of UGT2B family isoforms. Thus, cells expressing UGT 2B4, 2B7, 2B10, and 2B15 were lysed by probe sonication, 3 x 1 s with cooling on ice for 3 min between pulses, and lysates were stored at -70°C in phosphate buffer (0.1 M, pH 7.4) until measurement of enzyme activity.

Measurement of M3G and M6G Formation. Incubations contained morphine (6–11 concentrations; see Fig. 1), UDPGA (10 mM), MgCl₂ (5 mM), and microsomal or lysate protein (0.45 mg) in phosphate buffer (0.1 M, pH 7.4) in a total volume of 0.3 ml. Reactions were initiated by the addition of UDPGA and performed at 37°C for 90 min. Following the addition of perchloric acid (11.6 M, 0.012 ml) and 4MUG (the assay internal standard, 1 pmol), samples were vortex mixed and then centrifuged (1500g for 10 min). A 0.2-ml aliquot of the supernatant fraction was added to an Eppendorf tube containing KOH (2 M, 0.012 ml). M3G and M6G concentrations were quantitated using a specific high-performance liquid chromatographic method with fluorescence detection (Stone et al., 1998). Overall assay imprecision was <10% for substrate concentrations in the range 0.025 to 10 mM.

View larger version (23K): [in this window] [in a new window]   FIG. 1. Eadie-Hofstee plots for M3G formation by UGT1A1 (A) and UGT1A3 (B); panels C and D show Eadie-Hofstee plots for M3G () and M6G () formation by UGT2B7 from fitting to a biphasic Michaelis-Menten (C) and two-site (D) model. The inset in panels C and D are a magnification of the plots for M6G formation. Points represent experimental data, and curves were generated from model-fitting.

Measurement of 4MUG Formation. To confirm expression of individual UGTs, lysates or microsomes prepared from HK293 cells were tested for glucuronidation of the nonselective UGT substrate 4MU using a previously published fluorescence assay (Sorich et al., 2002). The 4MU concentrations used were 100 and 1000 µM. Overall assay imprecision was <3% at these substrate concentrations.

Data Analysis. All data points represent the mean of duplicate estimations. The kinetic parameters K_m and V_max were calculated from untransformed data by nonlinear least-squares regression using GraFit (Erithacus Software, Horley, Surrey, UK). Data were fitted to the Michaelis-Menten equations for a single- and two-enzyme model with a weighting of 1/y, and to the two-site model described by Kenworthy et al. (2001).

where [S] is substrate concentration, K_s is the substrate dissociation constant and and ß are binding factors that reflect changes in K_s and product formation (K_p), respectively. Goodness of fit was determined by comparison of statistical parameters (² and Akaike information criterion values) between the models and a reduction on the standard errors of the parameter estimates. Kinetic data are reported in Table 1 as mean ± S.E. of fit.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Apart from UGT2B4 and UGT2B10, 4MU glucuronidation activity was measurable (>10 pmol/min · mg at a 4MU concentration of 100 or 1000 µM) for all recombinant UGT isoforms (data not shown). Formation of 4MUG by UGT2B4, but not UGT2B10, was however confirmed using a more sensitive radiometric thin-layer chromatographic procedure (Jin et al., 1997). UGT 1A1, 1A3, 1A6, 1A8, 1A9, 1A10, and 2B7 all catalyzed morphine 3-glucuronidation, whereas UGT 2B4, 2B10, and 2B15 lacked the capacity to glucuronidate morphine. M3G formation kinetics by the UGT1A family isoforms were consistent with a single-enzyme Michaelis-Menten model, with apparent K_m values ranging from 2.6 to 37.4 mM. Derived kinetic constants are summarized in Table 1, and Eadie-Hofstee plots for representative low- (UGT1A1) and high- (UGT1A3) affinity isoforms are shown in Fig. 1 (panels A and B). Considerable variation was observed in V_max values (Table 1). However, relative expression of the isoforms, which presents difficulties with UGT, was not determined, and the significance of this observation remains to be assessed.

In contrast to the UGT1A family isoforms, M3G formation by UGT2B7 (in cell lysates) exhibited atypical kinetics (Fig. 1, C and D). (M3G formation kinetics by microsomes prepared from HK293 cells expressing UGT2B7 also exhibited nonhyperbolic kinetics, but the lower activity of the microsomal preparation precluded full kinetic characterization.) Derived kinetic constants from fitting to a biphasic Michaelis-Menten model are given in Table 1. Apparent K_m values for the high- and low-affinity components were 0.42 and 8.3 mM, respectively. V_max values for the high- and low-affinity components differed 7.8-fold. Derived parameters using the two-site model were: K_s, 1.76 ± 0.78 mM; V_max, 109 ± 36 pmol/min · mg; , 3.40 ± 1.07; and ß, 1.97 ± 0.50. UGT2B7 was the only isoform that mediated morphine 6-glucuronidation. M6G formation also exhibited atypical kinetics (Fig. 1, C and D). Derived K_m values from the biphasic Michaelis-Menten model fit (Fig. 1C) were 0.97 ± 0.29 mM and 13.7 ± 4.0 mM (Table 1). Parameters generated from the two-site model (Fig. 1D) were: K_s, 1.41 ± 0.56 mM; V_max, 13.9 ± 3.8 pmol/min · mg; , 4.19 ± 1.15; and ß, 2.00 ± 0.42.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Morphine has been shown previously to be a substrate for UGT2B7, and the formation of M3G has been used as an index of human liver microsomal UGT2B7 activity. However, data presented here suggest that formation of M6G, rather than M3G, is a selective probe for UGT2B7 activity in human tissues since multiple isoforms potentially contribute to morphine 3-glucuronidation. Formation of M3G by UGT1A3 and 1A8 is consistent with previously published data (Green et al., 1998; Cheng et al., 1999). A number of human UGTs were not screened for their capacity to glucuronidate morphine in this study, namely, UGT 1A4, 2A1, 2B11, 2B17, and 2B28. UGT1A4 has been reported previously not to metabolize morphine (Green et al., 1998), and like UGT2B10, UGT2B11 is an "orphan" enzyme apparently lacking catalytic activity (Jin et al., 1993; Beaulieu et al., 1998). UGT2A1 is expressed predominantly in olfactory epithelium (Tukey and Strassburg, 2000) and thus would not contribute significantly to morphine elimination in vivo. Roles for UGT2B17 and 2B28 in drug metabolism have not been established but cannot be discounted.

Of the isoforms capable of metabolizing morphine, UGT 1A1, 1A3, 1A6, 1A9, and 2B7 are expressed in the liver and may potentially contribute to hepatic clearance. However, the low affinities of UGT 1A1, 1A6, and 1A9 suggest that involvement of these isoforms is likely to be minor at best. Expression of UGT 1A8 and 1A10 is limited to the gastrointestinal tract, and UGT 1A1, 1A3, 1A6, 1A9, and 2B7 have also been identified in this tissue (Tukey and Strassburg, 2000). Data reported here are consistent with a contribution of the gastrointestinal tract to the first-pass extraction of morphine (Milne et al., 1996).

The kinetics of M3G and M6G formation by UGT2B7 were adequately described by either a biphasic Michaelis-Menten model or a two-site model based on the simultaneous binding of two substrate molecules at identical sites. Both approaches have been adopted previously to analyze the biphasic kinetic behavior of certain reactions catalyzed by recombinant cytochromes P450 (Houston and Kenworthy, 2000; Hutzler and Tracy, 2002). The values for derived for the two-site model were both >1, indicating the decreased binding affinity of a second substrate molecule in the presence of the first at the active site (negative cooperativity) (Houston and Kenworthy, 2000). The equivalence of the two binding sites is indicated by similar binding affinities (K_s) of M3G and M6G for the active site. The factor ß reflects changes in the effective catalytic rate constant (K_p) as the result of an interaction between the two occupied sites. Whenever the equivalence of two substrate binding sites is assumed, the value of ß is 2 (V_max is equivalent to 2K_p[E]_t, where [E]_t is the total enzyme concentration), which was observed for both M3G and M6G formation. Although atypical kinetics have been described for drug metabolism by recombinant cytochromes P450 (Shou et al., 2001; Galetin et al., 2002; Hutzler and Tracy, 2002), the phenomenon of negative cooperativity has been rarely observed for either substrate kinetics or the effect of a modifier. Previous studies of morphine glucuronidation by UGT2B7 have not alluded to biphasic kinetics. Apparent K_m values reported previously for M3G and M6G formation ranged from 0.47 to 1.0 mM and 0.55 to 1.3 mM, respectively (Coffman et al., 1997, 1998).

This report provides confirmation of atypical kinetic properties of human UGTs. Using UGT2B7, evidence of negative cooperativity is presented, consistent with multisite interactions between morphine and this enzyme. The two-site model provides more realistic insight to the interactions of morphine at the UGT2B7 active site than the biphasic Michaelis-Menten model, although both generate reasonable fit. Studies with UGTs require careful design and detailed experimentation to delineate kinetic properties.

Andrew N. Stone
Peter I. Mackenzie
Aleksandra Galetin
J. Brian Houston
John O. Miners

Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Adelaide, Australia (A.N.S., P.I.M., J.O.M.); and School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (A.G., J.B.H.)

	Footnotes

 
This work was supported by a grant from the National Health and Medical Research Council of Australia. A.N.S. was the recipient of an Australian Postgraduate Award (Industry), funded by the Commonwealth of Australia Department of Employment, Education, Training and Youth Affairs in collaboration with Faulding Pharmaceuticals.

¹ Abbreviations used are: UGT, UDP-glucuronosyltransferase; UDPGA, UDP-glucuronic acid; M3G, morphine 3-glucuronide; M6G, morphine 6-glucuronide; 4MU, 4-methylumbelliferone; 4MUG, 4MU-ß-D-glucuronide.

Address correspondence to: Professor John O. Miners, Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, SA 5042, Australia. E-mail: john.miners{at}flinders.edu.au

	References

Top Abstract Materials and Methods Results Discussion References

 


Beaulieu M, Levesque E, Hum DW, and Belanger A (1998) Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2B11. Biochem Biophys Res Commun 248: 44-50.[CrossRef][Medline]

Cheng Z, Radominska-Pandya A, and Tephly TR (1999) Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27: 1165-1170.[Abstract/Free Full Text]

Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26: 73-77.[Abstract/Free Full Text]

Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25: 1-4.[Abstract/Free Full Text]

Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic approach. Drug Metab Dispos 30: 1512-1522.[Abstract/Free Full Text]

Green MD, King CD, Mojarrabi B, Mackenzie PI, and Tephly TR (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26: 507-512.[Abstract/Free Full Text]

Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28: 246-254.[Abstract/Free Full Text]

Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30: 355-362.[Free Full Text]

Jin C-J, Mackenzie PI, and Miners JO (1997) The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341: 207-211.[CrossRef][Medline]

Jin C-J, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) cDNA cloning and expression of two new members of the human UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194: 496-503.[CrossRef][Medline]

Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29: 1644-1651.[Abstract/Free Full Text]

Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene family: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7: 255-269.[Medline]

Milne RW, Nation RL, and Somogyi AA (1996) The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals and the importance of metabolites to the pharmacological effects of morphine. Drug Metab Rev 28: 345-472.[Medline]

Miners JO, Lillywhite KJ, and Birkett DJ (1988) In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. Biochem Pharmacol 37: 2839-2845.[CrossRef][Medline]

Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51: 347-369.[CrossRef][Medline]

Shou M, Lin Y, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, et al. (2001) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2: 17-36.[CrossRef][Medline]

Sorich MJ, Smith PA, McKinnon RA, and Miners JO (2002) Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12: 635-645.[CrossRef][Medline]

Stone AN, Mackenzie PI, Birkett DJ, and Miners JO (1998) Human liver microsomal morphine 3- and 6-glucuronidation. ISSX Proc 13: 106.

Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40: 581-616.[CrossRef][Medline]

This article has been cited by other articles:

				V. Uchaipichat, A. Galetin, J. B. Houston, P. I. Mackenzie, J. A. Williams, and J. O. Miners Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites Mol. Pharmacol., October 1, 2008; 74(4): 1152 - 1162. [Abstract] [Full Text] [PDF]

				S. Ohno, K. Kawana, and S. Nakajin Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties Drug Metab. Dispos., April 1, 2008; 36(4): 688 - 694. [Abstract] [Full Text] [PDF]

				Y. Mano, T. Usui, and H. Kamimura The UDP-Glucuronosyltransferase 2B7 Isozyme Is Responsible for Gemfibrozil Glucuronidation in the Human Liver Drug Metab. Dispos., November 1, 2007; 35(11): 2040 - 2044. [Abstract] [Full Text] [PDF]

				T. Kubota, B. C. Lewis, D. J. Elliot, P. I. Mackenzie, and J. O. Miners Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4 Mol. Pharmacol., October 1, 2007; 72(4): 1054 - 1062. [Abstract] [Full Text] [PDF]

				A. Rowland, P. Gaganis, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 137 - 147. [Abstract] [Full Text] [PDF]

				K. Bowalgaha, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners The Glucuronidation of {Delta}4-3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6{alpha}- and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7 Drug Metab. Dispos., March 1, 2007; 35(3): 363 - 370. [Abstract] [Full Text] [PDF]

				P. Madadi, G. Koren, J. Cairns, D. Chitayat, A. Gaedigk, J. S. Leeder, R. Teitelbaum, T. Karaskov, and K. Aleksa Safety of codeine during breastfeeding: Fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine Can Fam Physician, January 1, 2007; 53(1): 33 - 35. [Abstract] [Full Text] [PDF]

				O. Kerdpin, D. J. Elliot, P. I. Mackenzie, and J. O. Miners Sulfinpyrazone C-Glucuronidation Is Catalyzed Selectively by Human UDP-Glucuronosyltransferase 1A9 Drug Metab. Dispos., December 1, 2006; 34(12): 1950 - 1953. [Abstract] [Full Text] [PDF]

				S. Takeda, Y. Kitajima, Y. Ishii, Y. Nishimura, P. I. Mackenzie, K. Oguri, and H. Yamada INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE Drug Metab. Dispos., August 1, 2006; 34(8): 1277 - 1282. [Abstract] [Full Text] [PDF]

				L. Xu, D. M. Krenitsky, A. M. Seacat, J. L. Butenhoff, T. R. Tephly, and M. W. Anders N-GLUCURONIDATION OF PERFLUOROOCTANESULFONAMIDE BY HUMAN, RAT, DOG, AND MONKEY LIVER MICROSOMES AND BY EXPRESSED RAT AND HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., August 1, 2006; 34(8): 1406 - 1410. [Abstract] [Full Text] [PDF]

				A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062. [Abstract] [Full Text] [PDF]

				Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo Jr., et al. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., May 1, 2006; 34(5): 748 - 755. [Abstract] [Full Text] [PDF]

				Y. Goumon, A. Muller, E. Glattard, C. Marban, C. Gasnier, J.-M. Strub, S. Chasserot-Golaz, O. Rohr, G. B. Stefano, I. D. Welters, et al. Identification of Morphine-6-glucuronide in Chromaffin Cell Secretory Granules J. Biol. Chem., March 24, 2006; 281(12): 8082 - 8089. [Abstract] [Full Text] [PDF]

				V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) "PROBES" FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., March 1, 2006; 34(3): 449 - 456. [Abstract] [Full Text] [PDF]

				G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2005; 33(7): 1027 - 1035. [Abstract] [Full Text] [PDF]

				M. Tachibana, M. Tanaka, Y. Masubuchi, and T. Horie ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., June 1, 2005; 33(6): 803 - 811. [Abstract] [Full Text] [PDF]

				S. Takeda, Y. Ishii, M. Iwanaga, P. I. Mackenzie, K. Nagata, Y. Yamazoe, K. Oguri, and H. Yamada Modulation of UDP-Glucuronosyltransferase Function by Cytochrome P450: Evidence for the Alteration of UGT2B7-Catalyzed Glucuronidation of Morphine by CYP3A4 Mol. Pharmacol., March 1, 2005; 67(3): 665 - 672. [Abstract] [Full Text] [PDF]

				J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208. [Abstract] [Full Text] [PDF]

				J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232. [Abstract] [Full Text] [PDF]

				V. Uchaipichat, P. I. Mackenzie, X.-H. Guo, D. Gardner-Stephen, A. Galetin, J. B. Houston, and J. O. Miners HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID Drug Metab. Dispos., April 1, 2004; 32(4): 413 - 423. [Abstract] [Full Text] [PDF]

				A. Galetin, S. E. Clarke, and J. B. Houston MULTISITE KINETIC ANALYSIS OF INTERACTIONS BETWEEN PROTOTYPICAL CYP3A4 SUBGROUP SUBSTRATES: MIDAZOLAM, TESTOSTERONE, AND NIFEDIPINE Drug Metab. Dispos., September 1, 2003; 31(9): 1108 - 1116. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stone, A. N. Articles by Miners, J. O. Search for Related Content PubMed PubMed Citation Articles by Stone, A. N. Articles by Miners, J. O.